NO20051969L - Nukleosidderivater for behandling av hepatitt C virusinfeksjon. - Google Patents

Nukleosidderivater for behandling av hepatitt C virusinfeksjon.

Info

Publication number
NO20051969L
NO20051969L NO20051969A NO20051969A NO20051969L NO 20051969 L NO20051969 L NO 20051969L NO 20051969 A NO20051969 A NO 20051969A NO 20051969 A NO20051969 A NO 20051969A NO 20051969 L NO20051969 L NO 20051969L
Authority
NO
Norway
Prior art keywords
hepatitis
treatment
virus infection
nucleoside derivatives
nucleoside
Prior art date
Application number
NO20051969A
Other languages
English (en)
Inventor
Natalia B Dyatkina
Christopher Don Roberts
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of NO20051969L publication Critical patent/NO20051969L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det beskrives forbindelser, preparater og metoder for behandling av hepatitt C virusinfeksjoner.
NO20051969A 2002-09-30 2005-04-22 Nukleosidderivater for behandling av hepatitt C virusinfeksjon. NO20051969L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41522202P 2002-09-30 2002-09-30
US44316903P 2003-01-29 2003-01-29
PCT/US2003/031433 WO2004028481A2 (en) 2002-09-30 2003-09-30 Nucleoside derivatives for treating hepatitis c virus infection

Publications (1)

Publication Number Publication Date
NO20051969L true NO20051969L (no) 2005-05-24

Family

ID=32045309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051969A NO20051969L (no) 2002-09-30 2005-04-22 Nukleosidderivater for behandling av hepatitt C virusinfeksjon.

Country Status (13)

Country Link
US (2) US7425547B2 (no)
EP (1) EP1572097A4 (no)
JP (1) JP2006505537A (no)
KR (1) KR20050059199A (no)
AU (1) AU2003279797B2 (no)
CA (1) CA2499253A1 (no)
EA (1) EA200500584A1 (no)
MX (1) MXPA05003400A (no)
NO (1) NO20051969L (no)
NZ (1) NZ538457A (no)
PL (1) PL376043A1 (no)
TW (1) TW200418498A (no)
WO (1) WO2004028481A2 (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US20060234962A1 (en) * 2002-06-27 2006-10-19 Olsen David B Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
KR20050035194A (ko) * 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
TW200418498A (en) * 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
MXPA05006865A (es) * 2002-12-23 2005-12-12 Idenix Cayman Ltd Proceso para la produccion de profarmacos 3'-nucleosidos.
US7799908B2 (en) 2003-01-15 2010-09-21 Valeant Pharmaceuticals North America Synthesis and use of 2′-substituted-N6 -modified nucleosides
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2007509939A (ja) 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
WO2005054268A1 (en) 2003-10-27 2005-06-16 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7169918B2 (en) 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
SG10201501376XA (en) 2004-03-04 2015-04-29 Leuven K U Res & Dev Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
AU2005289517A1 (en) * 2004-09-24 2006-04-06 Centre National De La Recherche Scientifique Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
US7414031B2 (en) 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
WO2007084157A2 (en) * 2005-03-23 2007-07-26 Genelabs Technologies, Inc. Nucleoside prodrugs for treating viral infections
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
TWI406664B (zh) * 2006-03-30 2013-09-01 Univ Kyoto 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
TW200838550A (en) * 2007-02-09 2008-10-01 Novartis Ag Organic compounds
AU2012204097B2 (en) * 2007-02-09 2013-02-07 Novartis Ag Novel nucleoside analogs for treatment of viral infections
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US20090004140A1 (en) * 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
CN102014911A (zh) 2008-04-28 2011-04-13 默沙东公司 Hcv ns3蛋白酶抑制剂
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
ES2392611T3 (es) 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
WO2010015643A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
TW201100428A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted indolo-piperidine compounds
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
CN103391939B (zh) 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
US9809616B2 (en) * 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014152566A2 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
US20240165144A1 (en) * 2019-10-16 2024-05-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating innate immune signaling pathways
US20240262857A1 (en) * 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6160695A (ja) * 1984-08-30 1986-03-28 Arakawa Chiyoutarou Kk 新規なｎ↑６−置換アデノシン誘導体及びその製造法並びにそれを有効成分とする降圧薬
GB8712745D0 (en) * 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
DE4141454A1 (de) * 1991-11-25 1993-05-27 Schering Ag Neues verfahren zur herstellung von 2-fluorpurin-derivaten
ATE244259T1 (de) * 1992-02-12 2003-07-15 Chromagen Inc Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
DK62592D0 (no) * 1992-05-14 1992-05-14 Novo Nordisk As
WO1994018215A1 (en) 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
ES2203635T3 (es) * 1994-04-27 2004-04-16 Novartis Ag Nucleosidos y oligonucleotidos con grupos 2'-eter.
US6211154B1 (en) * 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
EP1017823B1 (en) * 1997-02-07 2004-07-14 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US6090937A (en) 1998-03-17 2000-07-18 Ajinomoto Co., Inc. Methods for producing nucleoside derivatives and intermediates therefor
US6475985B1 (en) * 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
BR0309581A (pt) * 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
US20040028931A1 (en) 2002-06-26 2004-02-12 Bletsos Ioannis V. Coated sheet materials and packages made therewith
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
TW200418498A (en) 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US7799908B2 (en) 2003-01-15 2010-09-21 Valeant Pharmaceuticals North America Synthesis and use of 2′-substituted-N6 -modified nucleosides

Also Published As

Publication number Publication date
MXPA05003400A (es) 2005-06-22
JP2006505537A (ja) 2006-02-16
WO2004028481A3 (en) 2005-10-20
CA2499253A1 (en) 2004-04-08
WO2004028481A2 (en) 2004-04-08
EA200500584A1 (ru) 2006-02-24
PL376043A1 (en) 2005-12-12
US7629320B2 (en) 2009-12-08
EP1572097A4 (en) 2010-02-17
EP1572097A2 (en) 2005-09-14
AU2003279797A1 (en) 2004-04-19
US7425547B2 (en) 2008-09-16
US20040147464A1 (en) 2004-07-29
TW200418498A (en) 2004-10-01
AU2003279797B2 (en) 2009-10-22
US20080249060A1 (en) 2008-10-09
KR20050059199A (ko) 2005-06-17
NZ538457A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
WO2004028481A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
CY1109012T1 (el) Παραγωγα νουκλεοσιδιου σαν αναστολεις της rna-εξαρτωμενης rna iϊκης πολυμepασης
EA200000840A1 (ru) Антивирусные производные пиримидина
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
GEP20084545B (en) Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
NO20060979L (no) Nye tricykliske nukleosider eller nukleotider som terapeutiske midler
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
EA200700243A1 (ru) Способы лечения гепатита с
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
NO20005839D0 (no) Preparater for behandling av HIV og andre virale infeksjoner
WO2007084413A3 (en) Methods for treating hepatitis c
AU2002364730A1 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
WO2003053344A3 (en) Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2002062290A3 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
DE50214416D1 (de) Vermehrung von viren in zellkultur
DOP2003000641A (es) Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
ATE555794T1 (de) Heilmittel gegen hepatitis
WO2003053332A3 (en) Composition and method for treating viral infection
CA2480583A1 (en) Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
NO20056100L (no) Nitrogeninneholdende heteroarylderivater
WO2004052905A3 (en) Antiviral nucleoside derivatives
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application